MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

Plus: Amphastar Pharmaceuticals files a patent for an intranasal pharmaceutical formulation with naloxone and bile acid.

• MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
• Adult participants with B-Cell Malignancies: A study to assess adverse events, change in disease activity, and how Oral ABBV-101 moves through the body.
• Amphastar Pharmaceuticals files a patent for an intranasal pharmaceutical formulation with naloxone and bile acid.
• Arcturus Therapeutics patents synthetic transfer RNA for genetic disorders.

MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

The MesoCancerVac by Amphera is currently in the developmental stage and is being designed specifically for the treatment of various types of cancer, including pancreatic adenocarcinoma, malignant pleural mesothelioma, metastasized pancreatic ductal adenocarcinoma, and peritoneal mesothelioma. The administration of this substance is conducted via intravenous and intradermal routes. The therapy employs autologous dendritic cells that have been pulsed with allogeneic tumor cell lysates, which are fragments of tumor cells. Dendritic cells (DCs) have the capacity to induce the activation of T cells that are specific to a particular antigen.

Adult participants with B-Cell Malignancies: A study to assess adverse events, change in disease activity, and how Oral ABBV-101 moves through the body.

ABBV-101 by  is a pharmaceutical compound currently under investigation for its potential therapeutic application in the treatment of Non-Hodgkin's Lymphoma (NHL). The study will consist of two phases: a dose escalation phase and a dose expansion phase. The primary objective of the dose escalation phase is to establish the maximum administered dose (MAD) or maximum tolerated dose (MTD) of ABBV-101.

In the dose expansion phase, the focus will be on evaluating the impact of ABBV-101 on disease activity in participants diagnosed with chronic lymphocytic leukemia (CLL) or non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL). The study aims to enroll approximately 188 adult participants with various subtypes of NHL across multiple sites worldwide.

During the Dose Escalation phase of the study, participants will be administered increasing oral doses of ABBV-101 until the Maximum Administered dose (MAD) or maximum tolerated dose (MTD) is established. This phase is expected to last approximately 60 months. During the dose expansion phase of the study, participants are administered oral ABBV-101 over a period of approximately 60 months.

The trial participants may experience a greater treatment burden in comparison to their usual standard of care. Participants are required to attend scheduled visits at an authorized institution, such as a hospital or clinic, throughout the duration of the study. The efficacy of the treatment will be regularly monitored through medical evaluations, blood analyses, and assessments of potential side effects.

Amphastar Pharmaceuticals files a patent for an intranasal pharmaceutical formulation with naloxone and bile acid.

Amphastar Pharmaceuticals has recently submitted a patent application for intranasal pharmaceutical formulations that incorporate naloxone or an opioid antagonist as the primary active ingredient. These formulations also include an absorption enhancer, specifically a bile acid or its salt. The formulation is designed to optimize the absorption of Naloxone, or the opioid antagonist, into the bloodstream through intranasal delivery, with a pH range of approximately 3 to 5.

Arcturus Therapeutics patents synthetic transfer RNA for genetic disorders.

Arcturus Therapeutics has recently submitted a patent application for a novel synthetic transfer RNA (tRNA) featuring an elongated anticodon loop. The tRNA has been specifically engineered to address genetic disorders such as cystic fibrosis, which arise from a specific type of mutation known as a nonsense mutation.

The synthetic transfer RNA (tRNA) is designed with an elongated anticodon loop that consists of two consecutive anticodon base triplets. These base triplets are capable of forming base pairs with two consecutive codon base triplets found on a messenger RNA (mRNA) molecule.

The base triplet of either the first or second anticodon has the ability to form a base pair with the base triplet of a stop codon on the mRNA.